Portal de Periódicos da CAPES

BRAF-activated lncRNA predicts gastrointestinal cancer patient prognosis: a meta-analysis

2016; Impact Journals LLC; Volume: 8; Issue: 4 Linguagem: Inglês

10.18632/oncotarget.14061

1949-2553

Yanghua Fan, Min-Hua Ye, Lei Wu, Miaojing Wu, Shi-Gang Lu, Xingen Zhu,

RNA modifications and cancer

// Yang-Hua Fan 1, * , Min-Hua Ye 1, * , Lei Wu 1 , Miao-Jing Wu 1 , Shi-Gang Lu 1 , Xin-Gen Zhu 1 1 Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, People's Republic of China * These authors contributed equally to this work Correspondence to: Xin-Gen Zhu, email: zxg2008vip@163.com Shi-Gang Lu, email: lvshigang1982@sina.com Keywords: BANCR, long non-coding RNA, gastrointestinal cancer, biomarker, meta-analysis Received: October 20, 2016 Accepted: December 13, 2016 Published: December 21, 2016 ABSTRACT BRAF activated non-coding RNA (BANCR) is often dysregulated in cancer. We performed a meta-analysis to clarify its functions as a prognostic indicator in malignant tumors. We searched the PubMed, Medline, OVID, Cochrane Library, and Web of Science databases to identify BANCR-related studies. Nine original studies and 898 total patients were included in the meta-analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were extracted from the included studies to determine the relationship between BANCR expression and patient overall survival (OS). Odds ratios (OR) were calculated using RevMan 5.3 software to assess associations between BANCR expression and pathological parameters. High BANCR expression correlated with lymph node metastasis (LNM) (OR = 3.41, 95% CI: 1.82–6.37, P = 0.0001), distant metastasis (DM) (OR = 2.98, 95% CI: 1.76–5.07, P < 0.0001), tumor stage (OR = 3.11, 95% CI: 1.89–5.12, Z = 3.25, P < 0.0001), and poor OS (pooled HR = 1.98, 95% CI: 1.20–3.27, P = 0.008) in gastrointestinal (GI) cancer patients, but not in non-GI cancer patients. Our results support the notion that BANCR as a promising prognostic biomarker in Chinese patients with GI cancer.